Biocon reported a 10% revenue increase in Q1 FY27, reaching ₹4,336 crore, with net profit rising to ₹141 crore. Management expects a stronger second half of the year, driven by recent US biosimilar launches like Yesafili. While the biopharma business shows momentum, investors should monitor the ongoing decline in the services segment and competitive pressures in the US market.
Biocon Limited has reported a positive start to the current fiscal year, with its June quarter performance showing growth in its core biopharma business. The company’s consolidated revenue from operations rose by 10% year-on-year, touching ₹4,336 crore. Its net profit showed a significant improvement, reaching ₹141 crore for the quarter, compared to ₹31 crore in the same period last year. Net profit before exceptional items jumped 245% to ₹145 crore, signaling improved operational focus.
Biosimilars Lead Growth
The company’s growth is primarily anchored by its biosimilars and generics segments. Revenue from the biosimilars business grew 16% to ₹2,855 crore, while generics recorded a 21% rise to ₹760 crore. Management remains optimistic about the second half of FY27, citing the recent US market launch of Yesafili (aflibercept-jbvf), which occurred in August 2026. This product, alongside new denosumab biosimilars, is expected to be a major contributor to earnings in the coming months.
Biocon management highlighted that recent US regulatory shifts, which now place more emphasis on analytical studies rather than mandatory Phase 3 comparative efficacy trials, may benefit the company. By securing waivers for Phase 3 studies on several pipeline products, the company aims to reduce development costs and improve speed to market. This regulatory environment is seen as a supportive factor for established manufacturers like Biocon.
Services Segment and Financial Health
Despite the growth in biopharma, the services segment (Syngene) remains a challenge. This segment reported a 16% decline in revenue to ₹736 crore, reflecting ongoing legacy issues that have impacted overall group performance. The recovery of this business unit is a key factor that investors are watching to gauge the company’s consolidated earnings trajectory.
On the balance sheet side, the company has made progress in reducing its financial burden. Interest costs for the quarter decreased by 23% year-on-year, reflecting successful efforts to pay down debt. This reduction in finance costs is helping the company improve its bottom line, contributing to the healthy EBITDA margin of 21% recorded in the quarter.
Investor Monitorables
The success of the second half of the year will largely depend on the actual uptake of the new US product launches and the company’s ability to manage high competitive intensity in global generic markets. While management is confident, potential risks remain, including market sensitivity to exchange rate volatility and the speed at which the services segment can return to growth. Investors may track the revenue ramp-up from recent launches and any commentary regarding the stabilization of the services business in the next quarterly updates.